Galecto, Inc. develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company, founded in 2011, builds on more than 10 years of research into galectins and galectin modulators, which combined with a strong patent estate gives Galecto a unique platform.

Tel: (+45) 70 70 52 10 – Email:

Follow us